Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ANT 1403

Next Previous
Drug Profile

ANT 1403

Alternative Names: ANT-1403

Latest Information Update: 18 May 2020

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Anterios
  • Class Biological factors; Skin disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hyperhidrosis

Most Recent Events

  • 08 May 2020 Allergan has been acquired and merged into AbbVie
  • 31 Jul 2013 Anterios completes a phase II trial in Hyperhidrosis in USA (NCT01799824)
  • 21 Jun 2013 Anterios completes enrolment in its phase II trial for Hyperhidrosis in USA (NCT01799824)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top